Τίτλος:
Oral estramustine and oral etoposide for hormone-refractory prostate
cancer
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Objectives. Estramustine and etoposide have been shown to inhibit the
growth of prostate cancer cells in experimental models. An in vivo
synergism of the two agents, when administered to patients with
metastatic prostate cancer refractory to hormone therapy, has been
reported, To confirm these results, we administered this combination to
a large number of patients with hormone-refractory prostate cancer
(HRPC).
Methods. Fifty-six patients with metastatic HRPC were treated with oral
estramustine 140 mg three times a day and oral etoposide 50 mg/m(2)/day
for 21 days. Therapy was discontinued for 7 days and the cycle was then
repeated. Therapy was continued until evidence of disease progression or
unacceptable toxicity occurred. To control for the possible interference
of an antiandrogen withdrawal effect, all patients discontinued
antiandrogen therapy and were not enrolled in the study unless there was
evidence of disease progression.
Results. Forty-five percent of 33 patients with measurable soft tissue
disease demonstrated an objective response, which included five complete
and ten partial responses, Among 52 patients with osseous disease, 17%
showed improvement and 50% showed stability of bone scan, Thirty
patients (58%) demonstrated a decrease of more than 50% in
pretreatment prostate-specific antigen (PSA) levels, The median survival
of all patients was 13 months. Good pretreatment performance status,
measurable disease response, improvement or stability of bone scan, and
PSA response were important predictors of longer survival.
Conclusions. We conclude that the combination of estramustine and
etoposide is an active and well-tolerated oral regimen in HRPC. (C)
1997, Elsevier Science Inc. All rights reserved.
Συγγραφείς:
Dimopoulos, MA
Panopoulos, C
Bamia, C
Deliveliotis, C and
Alivizatos, G
Pantazopoulos, D
Constantinidis, C and
Kostakopoulos, A
Kastriotis, I
Zervas, A
Aravntinos, G and
Dimopoulos, C
Εκδότης:
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI:
10.1016/S0090-4295(97)00323-3
